Aniline

Aniline

SCHEMBL4258488

COc1ccc(C(=O)ON)cc1.Nc1ccccc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.56
CES1 P23141 2/20 0.56
NPC1 O15118 4/20 0.55
RAB9A P51151 4/20 0.55
CDK5 Q00535 2/20 0.55
CDK5R1 Q15078 2/20 0.55
CA1 P00915 4/20 0.55
CA2 P00918 4/20 0.55
MAPT P10636 3/20 0.51
PKM P14618 1/20 0.51
PARP1 P09874 1/20 0.50
PARP10 Q53GL7 1/20 0.50
PARP2 Q9UGN5 1/20 0.50
PARP4 Q9UKK3 1/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
POLB P06746 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
MAPK1 P28482 1/20 0.48
HDAC3 O15379 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3665174 0.88 CA1 (0.69) CES2CES1NPC1RAB9ACDK5
SCHEMBL16241062 0.88 CA1 (0.69) CES2CES1NPC1RAB9ACDK5
Aniline SCHEMBL15936355 0.84 LMNA (0.54) CES2CES1NPC1RAB9AMAPT
Aniline SCHEMBL4252018 0.83 NPC1 (0.50) CES2CES1NPC1RAB9ACDK5
Aniline SCHEMBL4259194 0.83 PARP1 (0.57) CES2CES1NPC1RAB9ACDK5
Aniline SCHEMBL4259209 0.81 KDM4E (0.53) NPC1RAB9AMAPTMEN1KMT2A
Aniline SCHEMBL4256412 0.79 CES2 (0.50) CES2CES1NPC1RAB9AMAPT
SCHEMBL4049434 0.79 CA1 (0.63) CES2CES1NPC1RAB9ACA1
SCHEMBL1000847 0.78 LMNA (0.57) NPC1RAB9AMAPTPKMPARP10
Aniline SCHEMBL27848079 0.78 TDP1 (0.80) CES2CES1NPC1RAB9ACA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1745022-B1 HISTONE DEACETYLASE INHIBITOR PRODRUGS ATON PHARMA INC (US) 2014-08-13 EP claimed
US-8227636-B2 Histone deacetylase inhibitor prodrugs MERCK HDAC RESEARCH, LLC (US) 2012-07-24 US claimed
EP-1745022-B1 HISTONE DEACETYLASE INHIBITOR PRODRUGS ATON PHARMA INC (US) 2014-08-13 EP disclosed
US-8227636-B2 Histone deacetylase inhibitor prodrugs MERCK HDAC RESEARCH, LLC (US) 2012-07-24 US disclosed
US-20090023786-A1 Histone Deacetylase Inhibitor Prodrugs ALTON PHARMA, INC. (US) 2009-01-22 US disclosed
EP-1745022-A1 HISTONE DEACETYLASE INHIBITOR PRODRUGS Aton Pharma, Inc. (US) 2007-01-24 EP disclosed
WO-2005097747-A1 HISTONE DEACETYLASE INHIBITOR PRODRUGS ATON PHARMA, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023786-A1 Histone Deacetylase Inhibitor Prodrugs HDAC1, HDAC5, HDAC7 CES2 2048/4885CES1 1325/4885NPC1 2859/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.